Last updated 2026-07-20
- Raised Pre-Seed round led by NGT HealthCare II, Dec 2022
Total raised
—
Last: Undisclosed Round 2023-01
Stage
Pre-Seed
Founded
2023
Headcount
8
HQ
Nazareth, Israel
Sector
Health Tech & Life Sciences
About
Noxon develops a novel drug for oral treatment of fibrotic lung diseases. Its product, 3-CP, a stable organic radical belonging to the nitroxides group, has unique antioxidant properties and has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of the lung tissues in animal models of allergic asthma. The drug is intended for oral administration and other routes of administration. Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology characterized by progressive fibrosis of the lungs leading to respiratory failure and death with a median survival of about 3 years consequent to diagnosis.
Funding history · 1 round · — total
2022-12
Pre-Seed
Undisclosed
★ NGT HealthCare II
Q&A
- What is Noxon's primary focus?
- Noxon is focused on drug development for fibrotic lung diseases.
- When was Noxon founded?
- Noxon was founded in January 2023.
- What is Noxon's main product?
- Noxon's main product is 3-CP, a novel drug for oral treatment of fibrotic lung diseases, which has shown to reduce airway inflammation and hyper-responsiveness in animal models of allergic asthma.
- What is Noxon's current funding stage?
- Noxon is currently in the Pre-Seed funding stage.
- Which investor participated in Noxon's January 2023 funding round?
- NGT HealthCare II participated in Noxon's funding round in January 2023.
- What is Noxon's primary sector?
- Noxon's primary sector is Health Tech & Life Sciences.
- Where is Noxon headquartered?
- Noxon is headquartered in Nazareth, Israel.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B2C
Tags
pharmaceuticalsdrug-discoveryhealthcareoral-drugs
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ngt-healthcare2.com/noxon/ |
|---|
Identifiers & details
| Legal name | Noxon Ltd. |
|---|---|
| Founded | 2023 |
| Employees (exact) | 8 |
Radar intelligence
Patents
| EPO | 109 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | ngt-healthcare2.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516731973 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2023-01-02 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | ואדי אל-חאג' 13 נצרת |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |